PLK1 and fibrosis: BRD4 has been identified as a potential therapeutic target for fibrosis resulting from chronic inflammation, through its involvement in hepatic stellate cell activation and hepatic fibrosis development via the P300/H3K27ac/PLK1 axis [41] or the NF-kB pathway [44], as well as its role in mitigating S. japonicum granulomas resulting from egg deposition [23].